CN116568295B - 改善或治疗冠状病毒感染的化合物及方法 - Google Patents

改善或治疗冠状病毒感染的化合物及方法

Info

Publication number
CN116568295B
CN116568295B CN202180046668.8A CN202180046668A CN116568295B CN 116568295 B CN116568295 B CN 116568295B CN 202180046668 A CN202180046668 A CN 202180046668A CN 116568295 B CN116568295 B CN 116568295B
Authority
CN
China
Prior art keywords
sars
cov
acid
compounds
coronavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180046668.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN116568295A (zh
Inventor
罗吉孟
黃琤
Y·B·吴
梁惠如
林佩欣
江豪
邱韦中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiya Biotechnology Co ltd
Original Assignee
Jiya Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiya Biotechnology Co ltd filed Critical Jiya Biotechnology Co ltd
Publication of CN116568295A publication Critical patent/CN116568295A/zh
Application granted granted Critical
Publication of CN116568295B publication Critical patent/CN116568295B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180046668.8A 2020-05-01 2021-04-29 改善或治疗冠状病毒感染的化合物及方法 Active CN116568295B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018690P 2020-05-01 2020-05-01
US63/018,690 2020-05-01
PCT/US2021/029840 WO2021222534A1 (en) 2020-05-01 2021-04-29 Compounds and methods for prevention and treatment of coronavirus infections

Publications (2)

Publication Number Publication Date
CN116568295A CN116568295A (zh) 2023-08-08
CN116568295B true CN116568295B (zh) 2026-02-13

Family

ID=78292168

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180046668.8A Active CN116568295B (zh) 2020-05-01 2021-04-29 改善或治疗冠状病毒感染的化合物及方法

Country Status (7)

Country Link
US (1) US12433901B2 (https=)
EP (1) EP4142713A1 (https=)
JP (1) JP7805010B2 (https=)
CN (1) CN116568295B (https=)
AU (1) AU2021264554A1 (https=)
TW (1) TW202206080A (https=)
WO (1) WO2021222534A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023535714A (ja) * 2020-07-23 2023-08-21 アージル・バイオテック・ホールディング・カンパニー・リミテッド ウイルス感染を阻害するための方法および組成物
US20240408055A1 (en) * 2021-10-21 2024-12-12 Peking University Shenzhen Graduate School Use of anisomelic acid in preparation of pharmaceutical composition for inhibiting infection and replication of sars-cov-2 and variants

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI453026B (zh) * 2013-05-14 2014-09-21 Jenisa Biotechnology Corp Ltd 魚針草萃取物及其純化物抗流感病毒之用途
CN104869991A (zh) * 2012-08-28 2015-08-26 约翰·埃里克森 防风草酸的药物组合物及其应用
CN113521060A (zh) * 2020-04-17 2021-10-22 毓维生物科技股份有限公司 鱼针草内酯抗新型冠状病毒的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140105928A1 (en) * 2004-01-06 2014-04-17 Paul Edward Stamets Antiviral and antibacterial activity from medicinal mushrooms
CA2481489A1 (en) * 2002-11-29 2004-06-17 Morinaga Milk Industry Co., Ltd. Cysteine protease inhibitor
TWI389699B (zh) * 2009-02-13 2013-03-21 高雄醫學大學 用於誘導細胞凋亡之樟芝子實體乙醇萃取物及其製備方法
US7919665B2 (en) 2009-02-17 2011-04-05 Conocophillips Company Mercury removal from hydrocarbons
TW201231474A (en) * 2011-01-26 2012-08-01 Univ Kaohsiung Medical Triterpenoid composition of Antrodia cinnamomea, preparation and analysis method thereof
US9645651B2 (en) 2013-09-24 2017-05-09 Microsoft Technology Licensing, Llc Presentation of a control interface on a touch-enabled device based on a motion or absence thereof
US11253527B2 (en) * 2019-02-25 2022-02-22 Arjil Biotech Holding Company Limited Method and composition for inhibiting virus infection
WO2021202982A1 (en) * 2020-04-03 2021-10-07 Turtle Bear Holdings, Llc Compositions and methods for modulating inflammatory response
TW202200175A (zh) * 2020-04-28 2022-01-01 浩峰生物科技股份有限公司 牛樟芝萃取物(Ant-Ex)減少血管收縮素轉換酶2(ACE-2)蛋白質表現

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104869991A (zh) * 2012-08-28 2015-08-26 约翰·埃里克森 防风草酸的药物组合物及其应用
TWI453026B (zh) * 2013-05-14 2014-09-21 Jenisa Biotechnology Corp Ltd 魚針草萃取物及其純化物抗流感病毒之用途
CN113521060A (zh) * 2020-04-17 2021-10-22 毓维生物科技股份有限公司 鱼针草内酯抗新型冠状病毒的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIV-inhibitory diterpenoid from Anisomeles indica;M.Shahidul Alam 等;Fitoterapi;20200430;第71卷(第5期);第575页 *

Also Published As

Publication number Publication date
JP7805010B2 (ja) 2026-01-23
EP4142713A1 (en) 2023-03-08
US12433901B2 (en) 2025-10-07
WO2021222534A1 (en) 2021-11-04
US20210338690A1 (en) 2021-11-04
AU2021264554A1 (en) 2023-01-05
JP2023524274A (ja) 2023-06-09
TW202206080A (zh) 2022-02-16
CN116568295A (zh) 2023-08-08

Similar Documents

Publication Publication Date Title
Chiou et al. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease
Anirudhan et al. Targeting SARS‐CoV‐2 viral proteases as a therapeutic strategy to treat COVID‐19
KR20220146558A (ko) 항-코로나바이러스에서의 디설피람의 용도
CN116568295B (zh) 改善或治疗冠状病毒感染的化合物及方法
Ghosh et al. Progress in anti-SARS coronavirus chemistry, biology and chemotherapy
CN113262224A (zh) 奈非那韦在制备防治新冠肺炎药物中的应用
Chakraborty et al. NL-63: A better surrogate virus for studying SARS-CoV-2
KR20230011972A (ko) 코로나바이러스로 인한 질병을 치료 및/또는 예방하는 화합물 및 이의 용도
TWI905258B (zh) 預防及治療病毒感染之化合物及方法
US11679102B2 (en) Method for inhibiting virus infection and replication
TWI917417B (zh) 治療病毒感染之方法及組合物
JP2023535714A (ja) ウイルス感染を阻害するための方法および組成物
RU2829731C1 (ru) Применение дисульфирама при резистентности коронавируса
US20250214981A1 (en) Compound and application thereof in preparation of medicine for treating enterovirus-related diseases
Sirois et al. Discovery of potent anti-SARS-CoV Mpro inhibitors
US20230241067A1 (en) Targeting papain-like protease for broad-spectrum coronaviruses inhibition
Muturi et al. Discovery of Pre-Existing Drugs that Suppress the Replication of SARS-CoV-2 in Vitro
Aziz et al. Novel Coronavirus 2019: An Updated Overview
Zhai et al. Recent patents on treatment of severe acute respiratory syndrome (SARS)
CN116003508A (zh) 一种含氰基的硒代丁内酰胺化合物及其制备方法和用途
MAJUMDER et al. AJ Csian OURNALOF HEMISTRY AJ Csian OURNALOF HEMISTRY
Pyrc et al. HCoV-NL63 induces interleukin-6 and interleukin-8 expression

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant